Mitragyna speciosa (commonly known as kratom) is a tropical evergreen tree in the coffee family native to Southeast Asia. It is indigenous to Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea, where it has been used in herbal medicine since at least the nineteenth century. Kratom has opioid properties and some stimulant-like effects.
As of 2018[update], the efficacy and safety of kratom are unclear, and the drug was unapproved as a therapeutic agent due to the poor quality of the research. In 2019, the United States Food and Drug Administration (FDA) stated that there is no evidence that kratom is safe or effective for treating any condition. Some people take it for managing chronic pain, for treating opioid withdrawal symptoms, or for recreational purposes. The onset of effects typically begins within five to ten minutes and lasts for two to five hours.
Common minor side effects include appetite loss, erectile dysfunction, hair loss and constipation. More severe side effects may include respiratory depression (decreased breathing), seizure, addiction, and psychosis. Other side effects may include high heart rate and blood pressure, trouble sleeping, and, rarely, liver toxicity. When use is stopped, withdrawal symptoms may occur. Deaths have occurred with kratom both by itself and mixed with other substances. Serious toxicity is relatively rare and generally appears at high doses or when kratom is used with other substances.
Kratom is a controlled substance in 16 countries and, in 2014, the FDA banned importing and manufacturing of kratom as a dietary supplement. As of 2018[update], there is growing international concern about a possible threat to public health from kratom use. In some jurisdictions, its sale and importation have been restricted, and several public health authorities have raised alerts.
Mitragyna speciosa is an evergreen tree that can grow to a height of 25 m (82 ft). Its trunk may grow to a 0.9 m (3 ft) diameter. The trunk is generally straight, and the outer bark is smooth and grey. The leaves are dark green and glossy and can grow to over 14–20 cm (5.5–7.9 in) long and 7–12 cm (2.8–4.7 in) wide when fully open, are ovate-acuminate in shape, and opposite in growth pattern, with 12–17 pairs of veins. The flowers grow in clusters of three at the ends of the branches. The calyx-tube is 2 mm (0.08 in) long and has five lobes; the corolla-tube is 2.5–3 millimetres (0.098–0.12 in) long.
Mitragyna speciosa is indigenous to Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea. It was first formally described by the Dutch colonial botanist Pieter Korthals in 1839, who named it Stephegyne speciosa; it was renamed and reclassified several times before George Darby Haviland provided the final name and classification in 1859.:59
Powder produced from unspecified tissues of the plant
|Part(s) of plant||Leaves|
|Geographic origin||Southeast Asia|
|Main consumers||Worldwide (No. 1: Thailand)|
|Retail price||€6–15 per 10g (EU; as of 2011[update])|
As of 2013[update], kratom has been studied in cells and in animals, but no clinical trials have been conducted in the United States. The United States Drug Enforcement Administration (DEA) stated in 2013: "There is no legitimate medical use for kratom". In April 2019, the United States Food and Drug Administration (FDA) stated that there is no evidence that kratom is safe or effective for treating any condition, and there are no approved clinical uses for kratom.
In cultures where the plant grows, kratom has been used in traditional medicine. The leaves are chewed to relieve musculoskeletal pain and increase energy, appetite, and sexual desire in ways similar to khat and coca. The leaves or extracts from them are used to heal wounds and as a local anesthetic. Extracts and leaves have been used to treat coughs, diarrhea, and intestinal infections. They are also used as intestinal deworming agents in Thailand.
Kratom is often used by workers in laborious or monotonous professions to stave off exhaustion as well as a mood enhancer and painkiller. In Thailand, kratom was "used as a snack to receive guests and was part of the ritual worship of ancestors and gods". The herb is bitter and is generally combined with a sweetener.
Data on how often it is used worldwide are lacking, as it is not detected by typical drug-screening tests. Rates of kratom use appear to be increasing among those who have been self-managing chronic pain with opioids purchased without a prescription and are cycling (but not quitting) their use.
In 1836, kratom was reported to have been used as an opium substitute in Malaysia. Kratom was also used as an opium substitute in Thailand in the nineteenth century.
At low doses, kratom produces euphoric effects comparable to coca. At higher doses, kratom produces opioid-like effects. The onset of effects typically begins within five to ten minutes and lasts for two to five hours.
In Thailand, a 2007 survey found that the lifetime, past year, and past 30 days kratom usage rates were 2.32%, 0.81% and 0.57%, respectively, among respondents aged 12–65 years, and was the most widely used drug in Thailand.
Commercially available kratom may be mixed with other psychoactive drugs, such as caffeine and codeine. Starting in the 2010s, a tea-based cocktail known as "4×100" became popular among some young people across Southeast Asia and especially in Thailand. It is a mix of kratom leaves, cough syrup, Coca-Cola, and ice. Around 2011, people who consumed the cocktail were often viewed more negatively than users of traditional kratom, but not as negatively as users of heroin. As of 2012[update], use of the cocktail was a severe problem among youth in three provinces along the border of Malaysia and southern Thailand.
In the US, as of 2015[update], kratom was available in head shops and over the Internet; the prevalence of its use was unknown at the time. In the United States, kratom use increased rapidly between 2011 and 2017.
Mitragyna speciosa may cause many adverse effects and in November 2017 the Food and Drug Administration issued a public health advisory for the drug. A 2019 review listed as common side effects: decreased appetite, anorexia, weight loss, temporary erectile dysfunction, insomnia, sweating, hyperpigmentation, hair loss, tremor, and constipation.
At relatively low doses (1–5 g of raw leaves), at which there are mostly stimulant effects, side effects include contracted pupils and blushing; adverse effects related to stimulation include anxiety and agitation, and opioid-related effects like itching, nausea, loss of appetite, and increased urination begin to appear.
At moderate (5 to 15 g of raw leaves) doses and higher, at which opioid effects generally appear, additional adverse effects include tachycardia (an increased stimulant effect) as well as the opioid side effects of constipation, dizziness, hypotension, dry mouth, and sweating.
Long term use of high doses of kratom may lead to development of tolerance, dependence, and withdrawal symptoms on stopping, including loss of appetite, weight loss, decreased sexual drive, trouble sleeping, muscle spasms, muscle and bone pains, jerky movement, watery eyes, hot flushes, fever, diarrhea, restlessness, anger, and sadness. This may lead to resumption of use.
Frequent use of high doses of kratom may cause tremors, anorexia, weight loss, seizures, and psychosis. Serious toxicity is relatively rare and generally appears at high doses or when kratom is used with other substances.
In July 2016, the Centers for Disease Control issued a report stating that between 2010 and 2015, US poison control centers received 660 reports of exposure to kratom. Medical outcomes associated with kratom exposure were reported as minor (minimal signs or symptoms, which resolved rapidly with no residual disability) for 162 (24.5%) exposures, moderate (non-life-threatening, with no residual disability, but requiring some form of treatment) for 275 (41.7%) exposures, and major (life-threatening signs or symptoms, with some residual disability) for 49 (7.4%) exposures. Overall, 92.6% of outcomes were resolved with no residual disability. One death was reported in a person who was exposed to the medications paroxetine (an antidepressant) and lamotrigine (an anticonvulsant and mood stabilizer) in addition to kratom. For 173 (26.2%) exposure calls, no effects were reported, or poison center staff members were unable to follow up regarding effects.
A 2019 report from the American Association of Poison Control Centers (AAPCC) stated that kratom use was increasing rapidly, with 1807 kratom exposures and a 52-fold increase occurring over the years 2011 to 2017. Most exposures occurred intentionally by adult males in their homes, with 32% of the incidents requiring admission to a health care facility and half of the admissions as a serious medical condition. Multiple-substance exposures were associated with a higher number of hospitalizations than single-substance exposures, and involved 11 deaths, including two due to kratom alone. Postmortem toxicology testing detected multiple substances for almost all those who died, with fentanyl and fentanyl analogs being the most frequently identified co-occurring substances.
Overdoses of kratom are managed similarly to opioid overdoses, and naloxone can be considered to treat an overdose that results in a reduced impulse to breathe, despite mixed results for its utility, based on animal models.
From October 2017 to February 2018 in the United States, 28 people in 20 different states were infected with salmonella, an outbreak occurring from the consumption of contaminated pills, powder, tea or unidentified sources of kratom. An analytical method using whole genome sequencing applied to samples from the infected people indicated that the salmonella outbreak likely had a common kratom source.
Respiratory depression is the leading cause of death from opioid use. Although evidence is sparse, the risk from respiratory depression caused by taking Mitragyna speciosa appears to be low, but as of 2016[update] the Food and Drug Administration listed respiratory depression as a concern.
In rare cases, though with a dangerous delay, kratom use has been linked to acute liver injury with symptoms of abdominal discomfort, dark urine, itching and jaundice. Liver injury has been reported with a latency (time from first use to onset of symptoms) of median 20.6 days. Reported liver biopsies tend to show cholestasis, however blood biomarkers can show a range of cholestatic, mixed, or hepatocellular injury pattern. The majority of users do not seem to develop liver injury, and it is unclear which users are at heightened risk. The mechanism by which kratom causes liver damage in some people is unknown and poorly studied, but a model has been proposed.
Kratom overdose is a subject of concern in many countries because of the rising number of hospitalizations and deaths in which chronic kratom abuse is a contributing factor. According to clinical reviews, a kratom overdose can cause liver toxicity, seizures, coma, and death, especially when in combination with alcohol abuse. Between 2011 and 2017, forty-four deaths were kratom-related. However many cases could not be fully assessed because of limited information. People who died from kratom use typically have taken it in combination with other substances, or have underlying health conditions.
Over 18 months in 2016 and 2017, 152 overdose deaths involving kratom were reported in the United States, with kratom as the primary overdose agent in 91 of the deaths, and 7 with kratom being the only agent detected. Nine deaths occurred in Sweden during 2010–11 relating to use of Krypton, a mixture of kratom, caffeine and O-desmethyltramadol, a prescription opioid analgesic.
Many of the key psychoactive compounds in M. speciosa are indole alkaloids related to mitragynine, which is a tetracyclic relative of the pentacyclic indole alkaloids, yohimbine and voacangine. In particular, mitragynine and 7-hydroxymitragynine (7-HMG) compose significant proportions of the natural products isolable from M. speciosa; e.g., in one study, mitragynine was 12% by weight from Malaysian leaf sources, versus 66% from Thai sources, and 7-hydroxymitragynine constituted ~2% by weight. In addition, at least 40 other compounds have been isolated from M. speciosa leaves, including ~25 additional alkaloids, including raubasine/ajmalicine (originally isolated from Rauvolfia serpentina), corynantheidine (also found in Pausinystalia johimbe), as well as mitraphylline, mitragynine pseudoindoxyl, and rhynchophylline.
Detection in body fluids
The plant's active compounds and metabolites are not detected by a typical drug screening test, but can be detected by more specialized testing. Blood mitragynine concentrations are expected to be in a range of 10–50 μg/L in persons using the drug recreationally. Detection in body fluids is typically by liquid chromatography-mass spectrometry.
As of 2017[update], much of the pharmacology of kratom was not well understood, having stimulant effects at low doses, an opioid-like effect at higher doses, as well as sedative and sensory-suppressive effects.
Both mitragynine and 7-HMG have partial agonist activity at nanomolar concentrations at the human μ-opioid receptors; 7-HMG appears to have higher affinity. Other alkaloids have antagonist activity at micromolar concentrations, so effects of whole kratom may result from the interplay of these different alkaloids. Different assays on the human receptor yielded different results, and activities at mouse and guinea pig μ-opioid receptors appear to be different as well, and it is unknown which alkaloids are able to cross the blood brain barrier in humans, making in vitro and animal studies problematic to translate to humans. The binding of kratom alkaloids at human and model animal δ- and κ-opioid receptor subtypes was very unclear as of 2017[update].
Mitragynine also stimulates α2-adrenergic receptors, inhibiting the release of norepinephrine (noradrenaline); other compounds in this class include dexmedetomidine, which is used for sedation, and clonidine, which is used to manage anxiety and some symptoms of opioid withdrawal. This activity might explain why kratom can be dangerous when used in combination with other sedatives.
Mitragynine is metabolized in humans via phase I and phase II mechanisms with the resulting metabolites excreted in urine. In in vitro experiments, kratom extracts inhibited CYP3A4, CYP2D6, and CYP1A2 enzymes, which results in significant potential for drug interactions.
Australia and New Zealand
As of October 2016[update], it was not legal to market kratom for any use in which it was ingested. However, it could be marketed for other uses, such as incense. Health Canada has taken action against companies marketing it for ingestion.
As of 2011[update], the plant was controlled in Denmark, Latvia, Lithuania, Poland, Romania and Sweden. In the UK, since 2016, the sale, import, and export of kratom are prohibited under the Psychoactive Substances Act.
The use of kratom leaves, known locally as ketum, is prohibited in Malaysia under Section 30 (3) Poisons Act 1952. Although prohibited by statute, the use of kratom remains widely spread because the tree grows natively and tea decoctions are readily available in local communities. Certain parties have urged the government to penalize the use of kratom under the Dangerous Drugs Act instead of the Poisons Act, which would carry heavier penalties.
Possession of kratom leaves (Thai: ต้นกระท่อม, RTGS: ton krathom) was illegal in Thailand until 2018. The Thai government had passed the Kratom Act 2486, effective 3 August 1943, which made planting the tree illegal, in response to a rise in its use when opium became very expensive in Thailand and the Thai government was attempting to gain control of the opium market. In 1979, the Thai government placed kratom, along with marijuana, in Category V of a five category classification of narcotics. Kratom accounted for less than two percent of arrests for narcotics between 1987 and 1992.
In the United States, there is consideration to make kratom a Schedule I drug. In 2019, the FDA warned consumers that kratom remains unapproved for interstate commerce, may be unsafe in commercially available products, and is on an import alert which can lead to confiscation of imported supplies.
In April 2019, the FDA issued a statement declaring that kratom was not approved for any medical use, was potentially unsafe in commercial products available in the United States, and remained on an import alert where imported supplies would be confiscated. On April 4, 2018, the FDA issued the first mandatory recall in its history over concerns of salmonella contamination of several kratom-containing products. Samples of the products, manufactured by Triangle Pharmanaturals, and marketed under the brand name 'Raw Form Organics', tested positive for contamination and the manufacturer did not comply with federal requests for voluntary recall. FDA Commissioner Gottlieb stated that the recall was, "...based on the imminent health risk posed by the contamination of this product with salmonella" and not related to other regulatory concerns. Consumers were advised to immediately discard any such products to prevent serious health risks.
In February 2018, the commissioner of the FDA, Scott Gottlieb, released a statement describing further opioid-like properties of kratom and stating that it should not be used for any medical treatment or recreational use. Also in 2018, the FDA supervised the voluntary destruction of kratom dietary supplements by a nationwide distributor in Missouri, and encouraged all companies involved in kratom commerce to remove their products from the market. On February 26, the FDA warned a California manufacturer of a kratom product called "Mitrasafe" that the supplement was not confirmed as safe, was not approved as a dietary supplement or drug, and was illegal for interstate commerce.
In November 2017, the FDA cited serious concerns over the marketing and effects (including death) associated with the use of kratom in the United States, stating that "There is no reliable evidence to support the use of kratom as a treatment for opioid use disorder; there are currently no FDA-approved therapeutic uses of kratom... and the FDA has evidence to show that there are significant safety issues associated with its use."
On August 30, 2016, the Drug Enforcement Administration (DEA) announced its intention to place the active materials in the kratom plant into Schedule I of the Controlled Substances Act as a warning about an imminent hazard to public safety, citing over 600 calls to poison control centers between 2010 and 2015 and 15 kratom-related deaths between 2014 and 2016. This drew strong protests among those using kratom to deal with chronic pain or wean themselves off opioids or alcohol. A group of 51 members of the U.S. House of Representatives and a group of nine Senators each sent letters to acting DEA administrator Chuck Rosenberg protesting the listing and around 140,000 people signed an online White House Petition protesting it. The DEA noted the responses but said that it intended to go forward with the listing; a spokesman said: "We can't rely upon public opinion and anecdotal evidence. We have to rely upon science." In October 2016, the DEA withdrew its notice of intent while inviting public comments over a review period ending on December 1, 2016. As of July 2016, Alabama, Arkansas, Indiana, Vermont, and Wisconsin had made kratom illegal, and the US Army had forbidden soldiers from using it. Between February 2014 and July 2016, U.S. law-enforcement authorities "encountered 55 tons of kratom," or roughly "50 million individual doses," according to the International Narcotics Control Board.
- Mitragyna speciosa (Korth.) Havil. is an accepted name . Theplantlist.org. Retrieved 2013-12-26.
- "Mitragyna speciosa". Germplasm Resources Information Network (GRIN). Agricultural Research Service (ARS), United States Department of Agriculture (USDA). Retrieved 2013-12-26.
- Rech, MA; Donahey, E; Cappiello Dziedzic, JM; Oh, L; Greenhalgh, E (February 2015). "New drugs of abuse". Pharmacotherapy. 35 (2): 189–97. doi:10.1002/phar.1522. PMID 25471045. S2CID 206358469.
- Hassan, Z; Muzaimi, M; Navaratnam, V; Yusoff, NHM; Suhaimi, FW; Vadivelu, R; Vicknasingam, BK; Amato, D; von Hörsten, S; Ismail, NIW; Jayabalan, N; Hazim, AI; Mansor, SM; Müller, CP (2013). "From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction". Neurosci Biobehav Rev. 37 (2): 138–151. doi:10.1016/j.neubiorev.2012.11.012. ISSN 0149-7634. PMID 23206666. S2CID 8463133.
- Gottlieb, Scott (6 February 2018). "Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse". US Food and Drug Administration. Retrieved 6 February 2018.
- Cinosi, E; Martinotti, G; Simonato, P; Singh, D; Demetrovics, Z; Roman-Urrestarazu, A; Bersani, F. S; Vicknasingam, B; Piazzon, G; Li, J. H; Yu, W. J; Kapitány-Fövény, M; Farkas, J; Di Giannantonio, M; Corazza, O (2015). "Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries". BioMed Research International. 2015: 1–11. doi:10.1155/2015/968786. PMC 4657101. PMID 26640804.
- Warner ML, Kaufman NC, Grundmann O (2016). "The pharmacology and toxicology of kratom: from traditional herb to drug of abuse". Int. J. Legal Med. (Review). 130 (1): 127–38. doi:10.1007/s00414-015-1279-y. PMID 26511390. S2CID 2009878.
- White CM (2018). "Pharmacologic and clinical assessment of kratom". Am J Health Syst Pharm (Review). 75 (5): 261–267. doi:10.2146/ajhp161035. PMID 29255059.
- "FDA and kratom". US Food and Drug Administration. 3 April 2019. Retrieved 8 August 2019.
- Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A (2019). "Characteristics of deaths associated with kratom use". J. Psychopharmacol. (Oxford) (Review). 33 (9): 1102–1123. doi:10.1177/0269881119862530. hdl:2299/21622. PMID 31429622. S2CID 201095094.
- "Kratom (Mitragyna speciosa korth)" (PDF). U.S. Drug Enforcement Administration. January 2013. Archived from the original (PDF) on 11 June 2016.
- Marx, John; Walls, Ron; Hockberger, Robert (2014). "Chapter 156: Hallucinogens". Rosen's emergency medicine : concepts and clinical practice (Eighth ed.). London: Elsevier Health Sciences. pp. 2015–23. ISBN 9781455749874.
- Schimmel, Jonathan; Dart, Richard C. (Feb 2020). "Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review". Drugs. 80 (3): 263–283. doi:10.1007/s40265-019-01242-6. PMID 31919755. S2CID 210088143.
- "Kratom". LiverTox, National Library of Medicine, US National Institutes of Health. 9 March 2017. Retrieved 29 March 2017.
- Anwar, Mehruba; Law, Royal; Schier, Josh (2016-01-01). "Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers – United States, 2010–2015". MMWR. Morbidity and Mortality Weekly Report. 65 (29): 748–49. doi:10.15585/mmwr.mm6529a4. ISSN 0149-2195. PMID 27466822.
- "Mitragynine". Toxnet, National Library of Medicine, US National Institutes of Health. 14 February 2012. Retrieved 15 February 2018.
- "Import Alert 54-15; Detention without physical examination of dietary supplements and bulk dietary ingredients that are or contain Mitragyna speciosa or kratom". U.S. Food and Drug Administration. 20 December 2016. Retrieved 7 March 2018.
- "Kratom profile (chemistry, effects, other names, origin, mode of use, other names, medical use, control status)". Page last updated 8 January 2015: European Monitoring Centre for Drugs and Drug Addiction. Retrieved 12 September 2016.CS1 maint: location (link)
- "DEA Announces Intent to Schedule Kratom: SE Asian drug is imminent hazard to public safety". US Drug Enforcement Administration. 30 August 2016. Archived from the original on 15 September 2016. Retrieved 31 August 2016.
- Eisenman, Sasha W. (2014). "Chapter 5. The Botany of Mitragyna speciosa (Korth.) Havil. and Related Species". In Raffa, Robert B. (ed.). Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium. CRC Press. pp. 57–76. ISBN 978-1-4822-2519-8.
- Adkins, Jessica E.; Edward W. Boyer; Christopher R. McCurdy (2011-05-01). "Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity". Current Topics in Medicinal Chemistry. 11 (9): 1165–75. doi:10.2174/156802611795371305. PMID 21050173.
- Department of Health and Aging Therapeutic Goods Administration (26 February 2004). National Drugs and Poisons Schedule Committee (PDF). 40th meeting. Government of Australia. pp. 103–105.
- "Unauthorized "Sāj" kratom products seized from two Edmonton stores may pose serious health risks". Health Canada. Canada. 4 May 2018. Retrieved 8 August 2018.
- Tave, Steven J. (26 February 2018). "FDA warning letter to Industrial Chemicals, LLC, and INI Botanicals" (PDF). Office of Dietary Supplement Programs, Center for Food Safety and Applied Nutrition, US Food and Drug Administration. Retrieved 7 March 2018.
- Cinosi, Eduardo; Martinotti, Giovanni; Simonato, Pierluigi; Singh, Darshan; Demetrovics, Zsolt; Roman-Urrestarazu, Andres; Bersani, Francesco Saverio; Vicknasingam, Balasingam; Piazzon, Giulia; Li, Jih-Heng; Yu, Wen-Jing (2015). "Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries". BioMed Research International. 2015: 1–11. doi:10.1155/2015/968786. ISSN 2314-6133. PMC 4657101. PMID 26640804.
- Singh, Darshan; Narayanan, Suresh; Vicknasingam, Balasingam; Corazza, Ornella; Santacroce, Rita; Roman‐Urrestarazu, Andres (2017). "Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia". Human Psychopharmacology: Clinical and Experimental. 32 (3): e2582. doi:10.1002/hup.2582. ISSN 1099-1077. PMID 28544011.
- Singh, Darshan; Narayanan, Suresh; Vicknasingam, Balasingam (September 2016). "Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature". Brain Research Bulletin. 126 (Pt 1): 41–46. doi:10.1016/j.brainresbull.2016.05.004. PMID 27178014. S2CID 3952688.
- Babu, Kavita M.; McCurdy, Christopher R.; Boyer, Edward W. (2008). "Opioid receptors and legal highs: Salvia divinorum and Kratom". Clinical Toxicology. 46 (2): 146–152: 149. doi:10.1080/15563650701241795. ISSN 1556-3650. PMID 18259963. S2CID 32501470.
- Garcia-Romeu, Albert; Cox, David J.; Smith, Kirsten E.; Dunn, Kelly E.; Griffiths, Roland R. (2020). "Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic". Drug and Alcohol Dependence. 208: 107849. doi:10.1016/j.drugalcdep.2020.107849. ISSN 0376-8716. PMC 7423016. PMID 32029298.
- Karch, Steven B.; Drummer, Olaf (2015). Karch's Pathology of Drug Abuse (Fifth ed.). CRC Press. p. 528. ISBN 9781439861479.
- Tanguay, Pascal (April 2011). "Kratom in Thailand: Decriminalisation and Community Control?" (PDF). Transnational Institute.
Young people feel the need to drink 4x100 in hidden settings due to fears of arrest by law enforcement. In one district, 21 of 39 villages reported the presence of 4x100 users in their community. Compared to traditional use, 4x100 users are subject to some measure of community discrimination, though community perceptions are far milder than for yaba or heroin users.
- Fuller, Thomas (23 July 2012). "A Fading Thai Drug Finds Its Resurgence in a Cocktail". The New York Times.
- Post, Sara; Spiller, Henry A.; Chounthirath, Thitphalak; Smith, Gary A. (20 February 2019). "Kratom exposures reported to United States poison control centers: 2011–2017". Clinical Toxicology. 57 (10): 847–854. doi:10.1080/15563650.2019.1569236. ISSN 1556-3650. PMID 30786220. S2CID 73507086.
- Stanciu, Cornel N.; Gnanasegaram, Samantha A.; Ahmed, Saeed; Penders, Thomas (January 2019). "Kratom Withdrawal: A Systematic Review with Case Series". Journal of Psychoactive Drugs. 51 (1): 12–18. doi:10.1080/02791072.2018.1562133. ISSN 2159-9777. PMID 30614408. S2CID 58643707.
- Olsen, Emily O’Malley; O’Donnell, Julie; Mattson, Christine L.; Schier, Joshua G.; Wilson, Nana (12 April 2019). "Unintentional Drug Overdose Deaths with Kratom Detected — 27 States, July 2016 – December 2017". MMWR. Morbidity and Mortality Weekly Report. 68 (14): 326–327. doi:10.15585/mmwr.mm6814a2. PMC 6459583. PMID 30973850.
- "Multistate Outbreak of Salmonella I 4,,12:b:- Infections Linked to Kratom Products | February 2018 | Salmonella". cdc.gov. Centers for Disease Control. 20 February 2018. Retrieved 22 February 2018.
- Beckett, Jaclyn R. (2014). "Non-Analgesic CNS Effects". In Raffa, Robert B. (ed.). Kratom and other mitragynines : the chemistry & pharmacology of opioids from. CRC Press. pp. 195–204. ISBN 9781482225181.
- Olsen EO, O’Donnell J, Mattson CL, Schier JG, Wilson N (12 April 2019). "Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected — 27 States, July 2016 – December 2017". MMWR. Morbidity and Mortality Weekly Report. 68 (14): 326–327. doi:10.15585/mmwr.mm6814a2. PMC 6459583. PMID 30973850.CS1 maint: uses authors parameter (link)
- Mari A. Schaefer (April 13, 2019). "CDC: Kratom linked to 91 U.S. overdose deaths". Lodi News-Sentinel. The Philadelphia Inquirer. p. 16.
- "Kratom Caused 91 Overdose Deaths During 18-Month Period: CDC – Partnership News Service from the Partnership for Drug-Free Kids". Partnership to End Addiction | Where Families Find Answers. Retrieved 2020-08-05.
- Rosenbaum CD, Carreiro SP, Babu KM (2012). "Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines". Journal of Medical Toxicology. 8 (1): 15–32. doi:10.1007/s13181-011-0202-2. PMC 3550220. PMID 22271566.
- Gibbons, Simon & Arunotayanun, Warunya (2013). "Chapter 14. Natural Product (Fungal and Herbal): Novel Psychoactive Substances". Novel Psychoactive Substances: Classification, Pharmacology and Toxicology. pp. 345–362. doi:10.1016/B978-0-12-415816-0.00014-6. Retrieved January 24, 2020.CS1 maint: multiple names: authors list (link)[full citation needed]
- Takayama, Hiromitsu; et al. (2002). "Studies on the Synthesis and Opioid Agonistic Activities of Mitragynine-Related Indole Alkaloids: Discovery of Opioid Agonists Structurally Different from Other Opioid Ligands". Journal of Medicinal Chemistry. 45 (9): 1949–56. doi:10.1021/jm010576e. PMID 11960505.
- Suhaimi FW, Yusoff NH, Hassan R, Mansor SM, Navaratnam V, Müller CP, Hassan Z (2016). "Neurobiology of Kratom and its main alkaloid mitragynine". Brain Res Bull. Mar 25 (Pt 1): 29–40. doi:10.1016/j.brainresbull.2016.03.015. PMID 27018165. S2CID 3952200.
- Prozialeck, WC; Jivan, JK; Andurkar, SV (2012). "Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic, and opioid-like effects". The Journal of the American Osteopathic Association. 112 (12): 792–99. PMID 23212430.
- Le D, Goggin MM, Janis GC (2012). "Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom". Journal of Analytical Toxicology. 36 (9): 616–25. doi:10.1093/jat/bks073. PMID 23024321.
- Baselt RC (2014). Disposition of toxic drugs and chemicals in man. Seal Beach, Calif.: Biomedical Publications. p. 1382. ISBN 978-0-9626523-9-4.
- Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D, Koyama F, Matsumoto K, Moriyama T, Yamamoto LT, Watanabe K, Murayama T, Horie S (2002). "Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands". J. Med. Chem. 45 (9): 1949–56. doi:10.1021/jm010576e. PMID 11960505.
- Kruegel AC, Grundmann O (2017). "The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse". Neuropharmacology. 134 (A): 108–20. doi:10.1016/j.neuropharm.2017.08.026. PMID 28830758. S2CID 24009429.
- White, CM (1 March 2018). "Pharmacologic and clinical assessment of kratom". American Journal of Health-System Pharmacy. 75 (5): 261–267. doi:10.2146/ajhp161035. PMID 29255059.
- "Annex I: ASEAN Guiding Principles For Inclusion into or Exclusion from the Negative List of Substances for Traditional Medicines and Health Supplements" (PDF). Association of South East Asian Nations (ASEAN). June 28, 2014. Archived from the original (PDF) on October 26, 2016. Retrieved September 12, 2016.
- "Medicines Regulations 1984". New Zealand Legislation. Retrieved 31 May 2017.
- Coles, Terri (14 October 2016). "After U.S. delayed decision on kratom, a look at Canada's laws on the psychadelic plant". Yahoo News Canada.
- "Health Product Advertising Complaints". Health Canada, Health Products and Food Branch. Archived from the original on 14 February 2017.
- Phil Heidenreich (27 June 2017). "Kratom, a controversial herbal product, seized from 2 Edmonton stores: Health Canada". Global News.
- "Psychoactive Substances Act 2016". The National Archives, HM Government Publishing. 9 September 2016.
- "MISUSE OF DRUGS (DESIGNATION) ORDER 2017" (PDF). STATUTORY INSTRUMENTS, S.I. No. 174 of 2017. Stationery Office, Dublin. 2017.
- "Amend the Act leaves the density of the Dangerous Drugs Act". 13 December 2012. Retrieved 18 April 2014.
- Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019;10:23–31. Published 2019 Jul 1. doi:10.2147/SAR.S164261
- Pengasih wants abuse of kratom leaves penalised under Dangerous Drugs Act. The Malaysian Insider. October 28, 2012.
- "Thailand legislature legalises medical cannabis and kratom". Aljazeera English. 26 December 2018. Retrieved 26 December 2018.
- Cheurprakobkit, Sutham (2000). "The drug situation in Thailand: the role of government and the police". Drug and Alcohol Review. 19 (1): 17–26. doi:10.1080/09595230096101.
- "Leafy highs: Kratom personal use push under way". Bangkok Post. 5 February 2020. Retrieved 5 February 2020.
- Prasert, Poungchompoo (4 October 2013). "Decision yet to be reached on making 'kratom' legal". The Nation.
- "HHS recommended that the DEA ban kratom, documents show – STAT". STAT. 9 November 2018. Retrieved 15 November 2018.
- "FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses". US Food and Drug Administration. 25 June 2019. Retrieved 16 January 2020.
- Chappell, Bill (4 April 2018). "FDA Orders An Unprecedented Recall After Kratom Company Ignored Its Requests". NPR. Retrieved 5 April 2018.
- FDA News Release. "FDA orders mandatory recall for kratom products due to risk of salmonella". Press Announcements. United States Food and Drug Administration. Retrieved 5 April 2018.
- "FDA oversees destruction and recall of kratom products; and reiterates its concerns on risks associated with this opioid". U.S. Food and Drug Administration. 21 February 2018. Retrieved 7 March 2018.
The FDA recommends that consumers not use these or any kratom products and dispose of any products currently in their possession. While the FDA is not aware of recent reports of illness specifically associated with the use of Divinity Products Distribution’s kratom-containing products, the agency asks health care professionals and consumers to report adverse events or quality problems associated with the use of Divinity Products Distribution’s products or any kratom product to the agency’s online Safety Reporting Portal
- "Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA advisory about deadly risks associated with kratom". U.S. Food and Drug Administration. 14 November 2017. Retrieved 14 November 2017.
Patients addicted to opioids are using kratom without dependable instructions for use and more importantly, without consultation with a licensed health care provider about the product’s dangers, potential side effects or interactions with other drugs. There’s clear data on the increasing harms associated with kratom. Calls to U.S. poison control centers regarding kratom have increased 10-fold from 2010 to 2015, with hundreds of calls made each year. The FDA is aware of reports of 36 deaths associated with the use of kratom-containing products. There have been reports of kratom being laced with other opioids like hydrocodone. The use of kratom is also associated with serious side effects like seizures, liver damage and withdrawal symptoms
- Silverman, Lauren (12 September 2016). "Kratom Advocates Speak Out Against Proposed Government Ban". NPR. Retrieved 12 September 2016.
- Ingraham, Christopher (September 30, 2016). "DEA defies senators' appeal to reconsider 'unprecedented' kratom ban". Washington Post.
- Stapleton, Christine (September 29, 2016). "Congress members ask DEA not to ban kratom: opioid research needed". Palm Beach Post.
- Nelson, Steven (September 30, 2016). "Kratom Will Remain Legal for Days, Possibly Longer". US News & World Report.
- "Kratom Gets Reprieve From Drug Enforcement Administration". NPR.org. Retrieved 2016-10-12.
- "Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7-Hydroxymitragynine Into Schedule I: A Proposed Rule by the Drug Enforcement Administration on 10/13/2016". Federal Register. Drug Enforcement Administration. 2016-10-13. Retrieved 2016-10-18.
- Brown, Melissa (May 20, 2016). "States ban kratom supplement over abuse worries". Associated Press via US News & World Report.
- Schwarz, Alan (2 January 2016). "Kratom, an Addict's Alternative, Is Found to Be Addictive Itself". The New York Times.
- Smith, Peter Andrey (2019-02-19). "The Herbal Supplement That Might Be a Deadly Drug". Outside Online. Retrieved 2019-02-20.
|Wikimedia Commons has media related to Mitragyna speciosa.|
|Scholia has a topic profile for Mitragyna speciosa.|
- Kratom (Mitragyna speciosa), from the European Monitoring Centre for Drugs and Drug Addiction, January 2015